SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

GIAPREZA

INVA·Innoviva, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available (FDA approved December 2017).
Why 4/10
GIAPREZA is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout in the next 12 months. The drug contributes to Innoviva's growing IST product sales but is one of several assets in a diversified company. ImpactScore is 4 per the rubric for an approved commercial drug with no upcoming binary catalyst.
Actionable Insight NEUTRAL

GIAPREZA has no upcoming FDA decision or pivotal readout; the next catalyst for Innoviva is the Q4 2026 earnings report (likely February 2027), where GIAPREZA's continued sales growth trajectory will be the key metric to watch. The drug's $23.1M quarterly run rate is on pace to help Innoviva hit its at-least-$150M full-year IST product sales guidance.

Price Chart

Loading chart...

Executive Summary

GIAPREZA (angiotensin II) is an FDA-approved vasopressor (approved December 2017) used in hospital ICUs to raise blood pressure in adults with septic or other distributive shock who do not respond to standard treatments. Innoviva acquired the drug along with La Jolla Pharmaceutical Company for $149 million in 2022. Under Innoviva's ownership, GIAPREZA has shown steady commercial growth: U.S. net sales reached $23.1 million in Q3 2026, contributing to 45% year-over-year growth in the company's Innoviva Specialty Therapeutics (IST) platform. The drug faces competition from cheap generic vasopressors like norepinephrine and vasopressin but occupies a unique niche as the only synthetic angiotensin II product on the market. With no pending FDA decision or pivotal trial readout, GIAPREZA is a steady commercial contributor within Innoviva's diversified portfolio (which also includes XACDURO, XERAVA, a large GSK royalty stream, and strategic investments), not a binary catalyst for the stock.

How It Works

GIAPREZA is a synthetic form of angiotensin II, a naturally occurring hormone in the body that tightens blood vessels to raise blood pressure. It is given intravenously in hospital intensive care units to treat adults with dangerously low blood pressure (septic shock or other distributive shock) who are not responding adequately to standard fluids and other blood-pressure-raising medications.

Trial Status

GIAPREZA was approved by the FDA in December 2017 based on the Phase 3 ATHOS-3 trial, which randomized 321 adults with septic or other distributive shock and demonstrated that angiotensin II effectively raised blood pressure. The drug is now a standard-of-care option for refractory distributive shock in ICU settings. No new pivotal trials are ongoing for the approved indication.

The Two-Sided Case

▲ Bull Case4
GIAPREZA is the first and only FDA-approved synthetic angiotensin II vasopressor, giving it a unique mechanism in the septic-shock treatment algorithm as an add-on when traditional vasopressors like norepinephrine fail.
U.S. net product sales of GIAPREZA reached $23.1 million in Q3 2026, contributing to 45% year-over-year growth in Innoviva's IST platform, which is on track to hit at least $150 million in full-year 2026 sales.
Innoviva acquired the drug for just $149M in 2022 and has successfully grown sales; at the current quarterly run rate, GIAPREZA alone is on pace for ~$85-90M in annualized U.S. sales, representing a strong return on the acquisition cost.
The drug benefits from hospital protocol adoption and clinical guidelines that recommend angiotensin II for refractory distributive shock, providing a moat against generic competition in the near-to-medium term.
▼ Bear Case4
GIAPREZA competes in the ICU vasopressor market against cheap, established generics like norepinephrine and vasopressin, limiting its pricing power and adoption to refractory cases only.
The drug was originally a laggard under La Jolla (prompting the $149M fire sale to Innoviva in 2022), and while sales have grown under Innoviva, the addressable market is narrow (refractory septic shock patients).
Patent protection is estimated to expire around 2031-2037, and with 11 Orange Book patents, generic entry remains a long-term overhang.
GIAPREZA is only one of several products in Innoviva's portfolio; the company's Q3 2026 GAAP net loss of $73.9M (driven by investment mark-to-market losses) and declining GSK royalty revenue ($58.1M vs $63.4M a year ago) create headline noise that can overshadow product sales growth.

Upcoming Catalysts

  • Q4 2026 / Full Year 2026 earnings report (expected February 2027): GIAPREZA sales trajectory and whether Innoviva hits its at-least-$150M IST product sales guidance.
  • Any label expansion or new clinical data for angiotensin II in perioperative vasoplegia (a secondary market being explored on the GIAPREZA website).
  • Patent challenge or generic entry developments (Orange Book lists 11 patents; estimated generic launch 2031-2037).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Innoviva, Inc. 8-K INVA ·Originating report

Sources · 10

Hover a chip for the title
1 drugs.com2 fiercepharma.com3 tradingview.com4 nasdaq.com5 biospace.com6 aol.com7 pharmaphorum.com8 drugpatentwatch.com9 giapreza.com10 sec.gov